ESMO Preview | Professor Jiong Wu: China-Originated Innovation Goes Global—Izalontamab Brengitecan Ushers in a New Era of Bispecific ADC Therapy for Breast Cancer
As the world's first approved EGFR × HER3 bispecific antibody–drug conjugate (ADC), Izecom (izalontamab brengitecan, BL-B01D1/iza-bren) features a dual-target structure designed to overcome the limitations associated with low or heterogeneous expression of a single target. It has demonstrated remarkable antitumor activity across multiple tumor types. The phase III PANKU-Breast02 study, jointly led by Professor Jiong Wu and Professor Jian Zhang of Fudan University Shanghai Cancer Center, reported positive results for both primary endpoints, progression-free survival (PFS) and overall survival (OS), in a high-profile late-breaking abstract (LBA) presentation at ASCO. In recognition of its breakthrough clinical value, the study also received the 2026 Innovative Research Award at this year's CSCO Annual Meeting. These achievements indicate that the clinical value of izalontamab brengitecan in breast cancer is attracting global attention and recognition.








